Co-Diagnostics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $166.1K | $146.0K | $263.9K | $145.4K | $162.9K | $50.3K | $149.3K | $641.1K |
| Cost of Revenue | $45.3K | $193.8K | $142.4K | $26.3K | $32.1K | $21.6K | $255.1K | $297.4K |
| Gross Profit | $120.8K | $-47.8K | $121.5K | $119.1K | $130.8K | $28.7K | $-105.7K | $343.7K |
| Gross Margin | 72.7% | -32.8% | 46.0% | 81.9% | 80.3% | 57.1% | -70.8% | 53.6% |
| Operating Expenses | ||||||||
| Research & Development | $4.2M | $5.9M | $5.1M | $4.5M | $4.7M | $4.9M | $4.8M | $4.9M |
| SG&A Expense | $1.5M | $2.5M | $1.9M | $1.8M | $2.6M | $2.8M | $5.8M | $4.3M |
| Operating Income | $-6.2M | $-9.2M | $-26.5M | $-7.0M | $-8.1M | $-8.6M | $-11.9M | $-10.2M |
| Operating Margin | -3,732.5% | -6,309.1% | -10,056.7% | -4,824.5% | -4,946.1% | -17,009.7% | -7,973.9% | -1,596.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-6.3M | $-9.1M | $-26.2M | $-7.1M | $-7.7M | $-7.5M | $-11.0M | $-9.7M |
| Income Tax Expense | $19.2K | $520 | $-473.7K | $-1.2M | $12.3K | $12.0K | $-8.2K | $22.2K |
| Net Income | $-6.3M | $-9.1M | $-25.7M | $-5.9M | $-7.7M | $-7.5M | $-11.0M | $-9.7M |
| Net Margin | -3,782.4% | -6,262.3% | -9,755.1% | -4,049.3% | -4,745.0% | -14,983.5% | -7,387.4% | -1,512.4% |
| EPS (Basic) | $-1.46 | $-4.06 | $-21.04 | $-0.16 | $-7.00 | $-7.05 | $-36.34 | $-0.32 |
| EPS (Diluted) | $-1.46 | $-4.06 | $-21.04 | $-0.16 | $-7.00 | $-7.05 | $-36.34 | $-0.32 |
| Shares Outstanding (Basic) | 4.3M | 2.3M | 1.3M | 37.9M | 1.1M | 1.1M | 1.0M | 30.5M |
| Shares Outstanding (Diluted) | 4.3M | 2.3M | 1.3M | 37.9M | 1.1M | 1.1M | 1.0M | 30.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |